182 related articles for article (PubMed ID: 21855335)
21. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
Zhao F; Zhang J; Zhang L; Hao Y; Shi C; Xia G; Yu J; Liu Y
Bioorg Med Chem; 2016 Sep; 24(18):4281-4290. PubMed ID: 27448775
[TBL] [Abstract][Full Text] [Related]
22. 1,3-Disubstituted-imidazo[1,5-a]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitors.
Mulvihill MJ; Ji QS; Werner D; Beck P; Cesario C; Cooke A; Cox M; Crew A; Dong H; Feng L; Foreman KW; Mak G; Nigro A; O'Connor M; Saroglou L; Stolz KM; Sujka I; Volk B; Weng Q; Wilkes R
Bioorg Med Chem Lett; 2007 Feb; 17(4):1091-7. PubMed ID: 17127062
[TBL] [Abstract][Full Text] [Related]
23. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
24. Discovery of (E)-5-(benzylideneamino)-1H-benzo[d]imidazol-2(3H)-one derivatives as inhibitors for PTK6.
Shim HJ; Yang HR; Kim HI; Kang SA; No KT; Jung YH; Lee ST
Bioorg Med Chem Lett; 2014 Oct; 24(19):4659-4663. PubMed ID: 25205190
[TBL] [Abstract][Full Text] [Related]
25. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
[TBL] [Abstract][Full Text] [Related]
26. Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors.
Sleebs BE; Nikolakopoulos G; Street IP; Falk H; Baell JB
Bioorg Med Chem Lett; 2011 Oct; 21(19):5992-4. PubMed ID: 21852129
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors.
Cui S; Wang Y; Wang Y; Tang X; Ren X; Zhang L; Xu Y; Zhang Z; Zhang ZM; Lu X; Ding K
Eur J Med Chem; 2019 Oct; 179():470-482. PubMed ID: 31271959
[TBL] [Abstract][Full Text] [Related]
28. Anchor-based classification and type-C inhibitors for tyrosine kinases.
Hsu KC; Sung TY; Lin CT; Chiu YY; Hsu JT; Hung HC; Sun CM; Barve I; Chen WL; Huang WC; Huang CT; Chen CH; Yang JM
Sci Rep; 2015 Jun; 5():10938. PubMed ID: 26077136
[TBL] [Abstract][Full Text] [Related]
29. Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells.
Bouloc N; Large JM; Kosmopoulou M; Sun C; Faisal A; Matteucci M; Reynisson J; Brown N; Atrash B; Blagg J; McDonald E; Linardopoulos S; Bayliss R; Bavetsias V
Bioorg Med Chem Lett; 2010 Oct; 20(20):5988-93. PubMed ID: 20833547
[TBL] [Abstract][Full Text] [Related]
30. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and SAR studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off-target kinase selectivity.
Voss ME; Rainka MP; Fleming M; Peterson LH; Belanger DB; Siddiqui MA; Hruza A; Voigt J; Gray K; Basso AD
Bioorg Med Chem Lett; 2012 May; 22(10):3544-9. PubMed ID: 22503250
[TBL] [Abstract][Full Text] [Related]
32. Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases.
Gingipalli L; Block MH; Bao L; Cooke E; Dakin LA; Denz CR; Ferguson AD; Johannes JW; Larsen NA; Lyne PD; Pontz TW; Wang T; Wu X; Wu A; Zhang HJ; Zheng X; Dowling JE; Lamb ML
Bioorg Med Chem Lett; 2018 May; 28(8):1336-1341. PubMed ID: 29559278
[TBL] [Abstract][Full Text] [Related]
33. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER
Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169
[TBL] [Abstract][Full Text] [Related]
34. Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4.
Mitchell SA; Danca MD; Blomgren PA; Darrow JW; Currie KS; Kropf JE; Lee SH; Gallion SL; Xiong JM; Pippin DA; DeSimone RW; Brittelli DR; Eustice DC; Bourret A; Hill-Drzewi M; Maciejewski PM; Elkin LL
Bioorg Med Chem Lett; 2009 Dec; 19(24):6991-5. PubMed ID: 19879134
[TBL] [Abstract][Full Text] [Related]
35. Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.
Martínez González S; Hernández AI; Varela C; Lorenzo M; Ramos-Lima F; Cendón E; Cebrián D; Aguirre E; Gomez-Casero E; Albarrán MI; Alfonso P; García-Serelde B; Mateos G; Oyarzabal J; Rabal O; Mulero F; Gonzalez-Granda T; Link W; Fominaya J; Barbacid M; Bischoff JR; Pizcueta P; Blanco-Aparicio C; Pastor J
Bioorg Med Chem Lett; 2012 Aug; 22(16):5208-14. PubMed ID: 22819764
[TBL] [Abstract][Full Text] [Related]
36. Divergent synthesis of kinase inhibitor derivatives, leading to discovery of selective Gck inhibitors.
Matsumaru T; Inai M; Ishigami K; Iwamatsu T; Maita H; Otsuguro S; Nomura T; Matsuda A; Ichikawa S; Sakaitani M; Shuto S; Maenaka K; Kan T
Bioorg Med Chem Lett; 2017 May; 27(10):2144-2147. PubMed ID: 28385506
[TBL] [Abstract][Full Text] [Related]
37. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
Charrier JD; Durrant SJ; Golec JM; Kay DP; Knegtel RM; MacCormick S; Mortimore M; O'Donnell ME; Pinder JL; Reaper PM; Rutherford AP; Wang PS; Young SC; Pollard JR
J Med Chem; 2011 Apr; 54(7):2320-30. PubMed ID: 21413798
[TBL] [Abstract][Full Text] [Related]
38. Identification and SAR of a new series of thieno[3,2-d]pyrimidines as Tpl2 kinase inhibitors.
Ni Y; Gopalsamy A; Cole D; Hu Y; Denny R; Ipek M; Liu J; Lee J; Hall JP; Luong M; Telliez JB; Lin LL
Bioorg Med Chem Lett; 2011 Oct; 21(19):5952-6. PubMed ID: 21862328
[TBL] [Abstract][Full Text] [Related]
39. Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis.
Boga SB; Alhassan AB; Liu J; Guiadeen D; Krikorian A; Gao X; Wang J; Yu Y; Anand R; Liu S; Yang C; Wu H; Cai J; Zhu H; Desai J; Maloney K; Gao YD; Fischmann TO; Presland J; Mansueto M; Xu Z; Leccese E; Knemeyer I; Garlisi CG; Bays N; Stivers P; Brandish PE; Hicks A; Cooper A; Kim RM; Kozlowski JA
Bioorg Med Chem Lett; 2017 Aug; 27(16):3939-3943. PubMed ID: 28720503
[TBL] [Abstract][Full Text] [Related]
40. Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells.
Ikeda O; Mizushima A; Sekine Y; Yamamoto C; Muromoto R; Nanbo A; Oritani K; Yoshimura A; Matsuda T
Cancer Sci; 2011 Apr; 102(4):756-61. PubMed ID: 21205088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
